Registry for diagnosing and managing AL amyloidosis in Europe
Bonding Molecular Genotyping and Phenotyping to Outcome Measures in AL Amyloidosis: A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
Fondazione IRCCS Policlinico San Matteo di Pavia · NCT06205953
This study is creating a registry to help doctors better diagnose and manage AL amyloidosis in Europe by collecting patient information and samples to learn more about the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia (other) |
| Locations | 6 sites (Heidelberg and 5 other locations) |
| Trial ID | NCT06205953 on ClinicalTrials.gov |
What this trial studies
This initiative aims to create a comprehensive registry of new cases of AL amyloidosis across Europe, focusing on patients evaluated at referral centers. It will establish a biorepository and sample sharing network to investigate the disease mechanisms using advanced molecular technologies and big data analysis. The project seeks to enhance early diagnosis, understand the disease's natural history, and refine techniques for detecting minimal residual disease in patients who have responded to therapy.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who have been newly diagnosed with systemic AL amyloidosis and are treatment-naïve.
Not a fit: Patients with non-AL amyloidosis or those who have previously received treatment for AL amyloidosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this project could lead to improved diagnosis and management strategies for patients with AL amyloidosis.
How similar studies have performed: Other studies utilizing registries and advanced molecular techniques have shown promise in improving outcomes for similar conditions, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosis of systemic AL amyloidosis; * treatment-naïve; * age ≥18 years; * ability to understand and willingness to sign an informed consent; * planned follow-up at participating center. Exclusion Criteria: * non-AL amyloidosis; * previous treatment for AL amyloidosis.
Where this trial is running
Heidelberg and 5 other locations
- Medical Department, Amyloidosis Center, University Hospital, Im Neuenheimer Feld 672 — Heidelberg, Germany (RECRUITING)
- Fondazione IRCCS Policlinico San Matteo, Pavia, Viale Golgi 19, 27100 — Pavia, Italy (RECRUITING)
- UMC Utrecht, dept Hematology, Amyloid Expertise Center, Utrecht, Heidelberglaan — Utrecht, Netherlands (RECRUITING)
- Instituto de Investigación Sanitaria de Navarra (IdiSNA) C. de Irunlarrea, 3, 31008 Pamplona, Navarra — Pamplona, Spain (RECRUITING)
- University of Applied Sciences and Arts Northwestern Switzerland, Institute of Medical Engineering and Medical Informatics — Muttenz, Switzerland (ACTIVE_NOT_RECRUITING)
- Universidad de la Republica Hospital de Clinicas "Dr Manuel Quintela" — Montevideo, Uruguay (RECRUITING)
Study contacts
- Study coordinator: Giovanni Palladini
- Email: segreteria.amiloidosi@smatteo.pv.it
- Phone: +390382502994
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: AL Amyloidosis